Safety and efficacy of G2-S16 dendrimer as microbicide in healthy human vaginal tissue explants.
J Nanobiotechnology
; 20(1): 151, 2022 Mar 21.
Article
en En
| MEDLINE
| ID: mdl-35307031
ABSTRACT
BACKGROUND:
The absence of an effective treatment and vaccine in HIV-1 pandemic place preventive strategies such as safety and effective microbicide development as a central therapeutic approach to control HIV-1 pandemic nowadays.RESULTS:
Studies of cytotoxicity, immune population status, inflammation or tissue damage and mainly prophylactic inhibition of HIV-1 infection in vaginal human explants demonstrate the biosafety and effectivity of G2-S16 dendrimer. Human explants treated with G2-S16 dendrimer or treated and HIV-1 infected do not presented signs of irritation, inflammation, immune activation or T cell populations deregulation.CONCLUSIONS:
Herein we conclude that G2-S16 dendrimer has demonstrated sufficient efficacy, biosafety, effectivity and behavior in the closest to the real-life condition model represented by the human healthy donor vaginal tissue explants, to raise G2-S16 dendrimer as a promising candidate to clinical trials to develop an effective microbicide against HIV-1 infection.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Dendrímeros
/
Antiinfecciosos
Límite:
Female
/
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article